Abeona Therapeutics Inc (NASDAQ:ABEO) has been assigned a consensus recommendation of “Hold” from the ten ratings firms that are presently covering the stock, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $15.75.

Several equities analysts recently commented on ABEO shares. HC Wainwright initiated coverage on Abeona Therapeutics in a research report on Monday, August 12th. They set a “buy” rating and a $15.00 price target on the stock. Maxim Group downgraded Abeona Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, August 15th. Zacks Investment Research upgraded Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, July 30th. BidaskClub upgraded Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, June 17th. Finally, ValuEngine upgraded Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 1st.

Abeona Therapeutics stock traded up $0.01 during midday trading on Wednesday, hitting $2.20. 191,821 shares of the company were exchanged, compared to its average volume of 510,879. The company’s fifty day moving average price is $3.23 and its 200-day moving average price is $5.95. The company has a market cap of $108.50 million, a PE ratio of -1.85 and a beta of 1.89. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.54 and a quick ratio of 2.54. Abeona Therapeutics has a fifty-two week low of $2.12 and a fifty-two week high of $15.65.

Abeona Therapeutics (NASDAQ:ABEO) last released its quarterly earnings results on Friday, August 9th. The biopharmaceutical company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.13). Abeona Therapeutics had a negative return on equity of 59.99% and a negative net margin of 960.91%. On average, analysts expect that Abeona Therapeutics will post -1.7 EPS for the current fiscal year.

Institutional investors and hedge funds have recently modified their holdings of the stock. Tower Research Capital LLC TRC grew its stake in Abeona Therapeutics by 434.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 8,719 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 7,088 shares during the last quarter. BNP Paribas Arbitrage SA grew its stake in Abeona Therapeutics by 21,590.0% during the 1st quarter. BNP Paribas Arbitrage SA now owns 6,507 shares of the biopharmaceutical company’s stock worth $48,000 after buying an additional 6,477 shares during the last quarter. Ellington Management Group LLC bought a new position in Abeona Therapeutics during the 2nd quarter worth $50,000. Trexquant Investment LP bought a new position in Abeona Therapeutics during the 2nd quarter worth $53,000. Finally, D. E. Shaw & Co. Inc. bought a new position in Abeona Therapeutics during the 2nd quarter worth $59,000. Hedge funds and other institutional investors own 57.49% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

See Also: What is Compound Interest?

Analyst Recommendations for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.